FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS; Nouveau Marche: OXIS) (FWB: OXI), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that it was preparing to submit for evaluation Palosein and Orgotein, two anti-oxidant/anti-inflammatory compounds that have potential clinical use in the treatment of polonium exposure and as a defense against radiation, to the Biomedical Advanced Research and Development Agency (BARDA) within the U.S. Department of Health and Human Services and to Project BioShield for funding. OXIS is also in discussions with pharmaceutical companies regarding licensing of its technology.
